DRL also faces headwinds because of increasing competitive intensity in the generic market and exchange rate volatility.

A long-term investor mindset will help make money, focus on new products at pharma companies draws to a close, Meta’s latest ...

Currently, Nomura is factoring in a 5% decline in US revenues for Zydus Life in financial year 2026, in comparison to ...

Currently Dr Reddy’s, Cipla and Zydus derive significant portion of their earnings from generic Revlimid; Realisations on generic Revlimid can fall in second half of ...

Repurposed Drug use for cancer is exploding around the world. And today, New Year’s Day 2025, even Artificial Intelligence is ...

Dr Reddy’s share price rose nearly 4% after Nuvama Institutional Equities upgraded its rating to ’Buy’ with a target of ...

Dr. Reddys Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate the ...

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...

Nuvama assigned a target price of Rs 1,553 per share on Dr. Reddy's stock, implying an upside of 14.8% from the previous ...

B&K Securities is bullish on CarTrade Tech Ltd., and holds that the company is a classic non-linear business with growth ...

Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in ...